Dr. Salim Dhanji reports

ME THERAPEUTICS HOLDINGS INC. ANNOUNCES LISTING AND TRADING OF ITS COMMON SHARES ON THE CANADIAN SECURITIES EXCHANGE

ME Therapeutics Holdings Inc.'s common shares are approved for listing on the Canadian Securities Exchange, effective Oct. 12, 2023, and will commence trading on the CSE at the market open on the listing date under the symbol METX.

On Oct. 4, 2023, ME Therapeutics was issued a receipt for its final long-form prospectus dated Sept. 29, 2023, which is available under the company's profile on SEDAR+.

As of the listing date, ME Therapeutics has 23,561,105 shares outstanding. An aggregate of 18,727,772 shares are subject to escrow restrictions, of which: (i) 14,999,994 shares (including 12,525,429 shares which are also subject to escrow pursuant to National Policy 46-201) are subject to restrictions such that 10 per cent of these shares will be released on the listing date, and an additional 30 per cent released on the dates that are nine, 18 and 27 months after the listing date; (ii) one million shares are subject to restrictions such that 25 per cent of these shares will be released on the listing date and the remaining 75 per cent will be released on the date that is six months after the listing date; and (iii) 15,253,207 shares (including 12,525,429 shares which are also subject to the voluntary escrow noted above) are subject to escrow restrictions pursuant to National Policy 46-201, whereby 10 per cent are released on listing and an additional 15 per cent released on the dates that are six, 12, 18, 24, 30 and 36 months after the listing date.

ME Therapeutics Holdings Inc.

ME Therapeutics is an early-stage, Vancouver-based, biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. The company's main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-tumour immunity.

We seek Safe Harbor.